Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Ascendis Pharma (Nasdaq: ASND) has scheduled its third quarter 2024 financial results announcement and business update for November 14, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast or register for the teleconference through provided links. A replay will be available on the company's investor relations website for 30 days following the event.
Ascendis Pharma (Nasdaq: ASND) ha programmato l'annuncio dei suoi risultati finanziari per il terzo trimestre del 2024 e un aggiornamento aziendale per il 14 novembre 2024, dopo la chiusura del mercato americano. L'azienda organizzerà una conferenza telefonica e una diretta web alle 16:30 ora orientale nello stesso giorno. Gli investitori possono accedere alla diretta web o registrarsi per la teleconferenza tramite i link forniti. Una registrazione dell'evento sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda per 30 giorni dopo l'evento.
Ascendis Pharma (Nasdaq: ASND) ha programado el anuncio de sus resultados financieros del tercer trimestre de 2024 y una actualización empresarial para el 14 de noviembre de 2024, después del cierre del mercado en EE. UU. La compañía llevará a cabo una conferencia telefónica y una transmisión web a las 4:30 p.m. hora del Este el mismo día. Los inversores pueden acceder a la transmisión en vivo o registrarse para la teleconferencia a través de los enlaces proporcionados. Una repetición estará disponible en el sitio web de relaciones con inversores de la compañía durante 30 días después del evento.
Ascendis Pharma (Nasdaq: ASND)는 2024년 3분기 재무 실적 발표 및 사업 업데이트를 2024년 11월 14일에 미국 시장 마감 후로 예정하고 있습니다. 회사는 당일 동부 표준시 기준 오후 4시 30분에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 제공된 링크를 통해 실시간 웹캐스트에 접근하거나 전화 회의에 등록할 수 있습니다. 이벤트 후 30일 동안 회사의 투자자 관계 웹사이트에서 재생할 수 있습니다.
Ascendis Pharma (Nasdaq: ASND) a programmé l'annonce de ses résultats financiers pour le troisième trimestre 2024 et une mise à jour des activités pour le 14 novembre 2024, après la fermeture du marché américain. La société organisera une conférence téléphonique et un webinaire à 16h30, heure de l'Est, le même jour. Les investisseurs peuvent accéder au webinaire en direct ou s'inscrire à la téléconférence via les liens fournis. Un enregistrement sera disponible sur le site web des relations avec les investisseurs de l'entreprise pendant 30 jours après l'événement.
Ascendis Pharma (Nasdaq: ASND) hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 sowie ein Unternehmensupdate für den 14. November 2024 nach Börsenschluss in den USA terminiert. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten. Investoren können über die bereitgestellten Links auf den Live-Webcast zugreifen oder sich für die Telefonkonferenz registrieren. Ein Replay wird für 30 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report third quarter 2024 financial results and provide a business update on Thursday, November 14, 2024, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on November 14, 2024, at 4:30 p.m. Eastern Time (ET) to discuss its third quarter 2024 financial results.
Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.
About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (ii) Ascendis’ use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis’ products and product candidates; unforeseen safety or efficacy results in Ascendis’ development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis’ development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis’ business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 7, 2024, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma Group. © November 2024 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: | |
| Scott Smith | Melinda Baker | |
| Ascendis Pharma | Ascendis Pharma | |
| ir@ascendispharma.com | +1 (650) 709-8875 | |
| media@ascendispharma.com | ||
| Patti Bank | ||
| ICR Healthcare | ||
| +1 (415) 513-1284 | ||
| patti.bank@westwicke.com |
FAQ
When will Ascendis Pharma (ASND) report Q3 2024 earnings?
What time is Ascendis Pharma's (ASND) Q3 2024 earnings call?
How long will Ascendis Pharma's (ASND) Q3 2024 earnings call replay be available?
